Table 5.

Comparison of risankizumab steady-state exposures between non-Japanese and Japanese (at a 150 mg SC dose) patients with psoriasis (mean [SD] and median)

Parameter	Population
	Non-Japanese (phase III) [n = 1130]	Japanese [n = 102]
Cmax (µg/mL)	12.4 (3.29) 12.2	14.5 (3.44) 14.5
AUCτ (µg·day/mL)	494 (176) 481	559 (194) 522
Ctrough (µg/mL)	2.02 (1.18) 1.82	2.22 (1.26) 1.90

C_trough plasma concentration at the end of the dosing interval, SC subcutaneous, SD standard deviation, C_max maximal plasma concentration, AUC_τ area under the plasma concentration–time curve during a dosing interval, C_trough trough plasma concentrations